Chronic graft-versus-host disease (cGVHD) poses significant challenges in the management of patients who have undergone transplant procedures. Current treatment options often provide limited efficacy or unacceptable toxicity, highlighting the need for novel therapeutic strategies. The phase II AGAVE-201 trial investigated the potential of axatilimab, a high-affinity anti-CSF-1R monoclonal antibody, in patients with recurrent/refractory cGVHD. The
Health
Autologous stem-cell transplantation (ASCT) has been found to be more effective than CAR T-cell therapy in improving outcomes for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, according to a retrospective analysis. The study, presented at the American Society of Hematology (ASH) meeting, showed that patients who underwent ASCT had lower rates of
Bilateral mastectomy, once seen as a potential life-saving treatment for women with breast cancer and a BRCA1 pathogenic variant, may not provide any significant survival benefit, according to a recent international analysis. The study, presented at the San Antonio Breast Cancer Symposium by Kelly Metcalfe, RN, PhD, from the Women’s College Research Institute in Toronto,
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Currently, there is a lack of targeted therapies for TNBC, making the exploration of maintenance strategies crucial for improving patient outcomes. In the phase II KEYLYNK-009 trial, a
A randomized trial conducted by researchers at Odense University Hospital in Denmark has failed to demonstrate that low-dose naltrexone provides any significant pain relief for patients with fibromyalgia. The trial, which involved 99 patients, found that those assigned to naltrexone reported only a slight decline in pain intensity, with a mean decrease of 1.3 points
In a recent study presented at the International Gynecologic Cancer Society’s annual meeting, promising results were reported for trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in heavily pretreated patients with HER2-expressing gynecologic cancers. Dr. Ritu Salani from the University of California Los Angeles discusses the findings from the DESTINY-PanTumor02 trial and highlights the practice-changing potential of
A groundbreaking trial, known as the Renal Agenesis Fetal Therapy (RAFT) trial, has shown promising results in restoring amniotic fluid lost due to fetal renal underdevelopment before 26 weeks’ gestation. The study found that serial infusions of amniotic fluid significantly increased the rate of live births without posing any major risks to the mothers involved.
In a randomized IMerge trial, patients with lower-risk myelodysplastic syndromes (MDS) who relapsed or were refractory to standard treatment achieved improved rates of red blood cell (RBC) transfusion independence with an investigational, first-in-class telomerase inhibitor called imetelstat. This breakthrough therapy showed promising results in achieving sustained transfusion independence and potentially serving as a second-line treatment
The words “bone marrow biopsy” had never been on my radar until the day I met the oncologist in the emergency department. As a 24-year-old medical student, I had suddenly found myself faced with a cancer diagnosis that would completely alter the course of my life. The shock and uncertainty of that moment were overwhelming,
The so-called “Take Care of Maya” trial concluded recently, resulting in a substantial $261 million verdict against Johns Hopkins All Children’s Hospital of Florida. The jury found the hospital liable for various claims, including wrongful death, emotional distress, false imprisonment, and battery. The Kowalski family alleged that the hospital falsely reported Medical Child Abuse (MCA)